CREATE
TRANSFORMATIVE
MEDICINES
A global leader in innovative solutions for the discovery, development, and manufacture of novel nanoparticle medicines.
 

 

 

We are Counting the Hours, Minutes & Seconds... 
Ignite Logo
October 15, 2019

At Precision NanoSystems, we have made it our mission to accelerate the creation of transformative medicine that significantly impacts human well-being. In July of 2019, we launched the NxGen microfluidic mixing technology to better meet the needs of our customers as they advance their programs towards the clinic.

 

The Ignite embodies everything that made the NanoAssemblr Benchtop the workhorse of nanomedicine development for over 100 biopharma companies, while bringing the latest innovations developed for the NanoAssemblr cGMP system to the bench — saving time and money.

 

Over the next few weeks you will be hearing more about the NanoAssemblr Ignite. Here are a few highlights of Ignite:

 

We designed Ignite with the end in mind; PNI’s NxGen Technology is integrated across the NanoAssemblr allowing commercial scale manufacturing through a single mixer.

 

We built it for the future; the Ignite is expandable to enable development of new types of nanomedicines.

 

Finally, we focused on maximizing your time so you that you and your team spend the time where it matters.

 

Ignite is easy to use and intuitive in both design and function. We are hitting the road and showcasing this revolutionary technology in a location near you. Find local Workshops or see Ignite and our complete NanoAssemblr Platform at these conferences in 2019

 

Pre-Order Ignite now by contacting your local sales representative

Formulation Solutions Formulation Solutions Formulation Solutions
Rapidly prepare low-volume nanoparticle formulations with the push of a button on the Spark™ or learn how Formulation Solutions can help with proof-of-concept nanoparticle formulations.
Optimize a wide range of nanomedicine formulations with the NanoAssemblr® Benchtop or the Blaze  depending on your volumes to allow you to gather the data on the effectiveness, required dosing and safety of a new therapy.
Scalable manufacturing is a significant challenge to making revolutionary medicine and  Clinical Solution  is ready to assist you in your nanoparticle manufacturing process development.
You're In Good Company
<

 

  • “The NanoAssemblr® Blaze™ from Precision NanoSystems is very good for the rapid scale-up of nanoparticle-based formulations. We were able to seamlessly transition our formulation developed on the NanoAssemblr Benchtop to the Blaze instrument and make large scale batches on the Blaze. The Blaze instrument has saved us time, effort and precious materials.” - Muthusamy Jayaraman Senior Director, Head of Non-Viral Delivery at CRISPR Therapeutics
  • "As an Evonik affiliate specialized in liposomal drug delivery systems, we are pleased to offer our clients access to the NanoAssemblr GMP System, which will aid in the translation of drug candidates to clinical testing and ideally to commercial use."  - Don Enns, Vice President of Evonik Vancouver Laboratories
  • "We are excited about this promising collaboration and hope that it will propel our work forward as the ncRNA Core Facility focuses on the non-coding RNA portions of the genome for [the] discovery of novel biomarkers and targets for therapeutics from human disease tissue and clinical trial specimens."- Frank Slack, Director of the Harvard Medical School Initiative for RNA Medicine (HIRM) at BIDMC
  • "Ajinomoto Bio-Pharma Services has audited the PNI facilities in Vancouver and has qualified PNI's NanoAssemblr® GMP System and its components. We are excited to work with PNI to offer their purpose-designed manufacturing technology and unique nanomedicine expertise to our clients for the manufacture of nanoparticle-based medicines"  - Kristin DeFife, Ph.D., Vice President and Head of US Operations of Ajinomoto Bio-Pharma Services
>

Get Started

To learn how Precision NanoSystems accelerates nanomedicine development from an idea to clinical applications, contact our Technical Sales Team.

Get in Touch
Technology

NxGen logo

 

Our exclusive NxGen technology uses precisely controlled mixing to reproducibly generate optimal particles through a single mixer across scales. NxGen technology is at the heart of the NanoAssemblr® family, which provides manufacturing of nanoparticles at different scales suitable for all stages of nanomedicine development.

 Learn More.

 


Mixtures
Benchtop
Coming Soon: The NanoAssemblr® Ignite
Areas of Interest
Nanomedicines span many areas of interest. Explore resourceslike papers, application notes, scientific posters, webinars and more to see how nanotechnology is transforming medicine. 
Particles
over
70%
of top pharmaceutical companies work with PNI
200+

instruments are installed

worldwide

80+
biopharmaceutical labs use NanoAssemblr® instruments for nanomedicine drug development
Innovations that accelerate the drug development journey and enable the production of more sophisticated and powerful nanomedicines is our passion. We don’t do it alone, we pursue strategic collaborations that enable researchers to move quickly in the drug development process. Contact our Business Development Team.

 

 

 

 

 

PNI at 2019 BIO International Convention


Dr. James Taylor, CEO of Precision NanoSystems, successfully previewed NxGen microfluidic mixer by presenting on "How Precision NanoSystems’ NxGen Technology Drives the Creation of Transformative Nanomedicines” at the 2019 BIO International Convention.

License Agreement with Daiichi Sankyo

 

Daiichi Sankyo has signed a license agreement for use of the NanoAssemblr GMP System configuring a customized microfluidics-based GMP System that is fit-for-purpose and stage appropriate. 

Clinical Solutions Platform Launch

 

“Clinical Solutions is designed to provide a one-stop-shop for all nanomedicine clinical development needs, such as sourcing GMP excipients, developing analytical methods, building Quality Management Systems or accessing experienced Contract Manufacturing Organizations,” Precision NanoSystems' CFO, Euan Ramsay

Upcoming Events See All

October
13 - 16
2019

Annual Meeting of the Oligonucleotide Therapeutics Society (OTS)

The Oligonucleotide Therapeutics Society 2019 takes oligonucleotide research to its full therapeutic potential. Note: More details will become available soon.

November
03 - 06
2019

AAPS 2019 PharmSci 360

AAPS 2019 PharmSci 360 will combine all the energy of a large scientific conference with the intimacy of a small niche gathering.

November
11 - 13
2019

7th International mRNA Health Conference

The International mRNA Health Conference the premier meeting destination for industry and academic professionals to explore the rapidly advancing science and business of mRNA, providing participants a platform to network with colleagues, secure updates on advances in mRNA technol...

Resource Center

Publication - Summary

May 18, 2019

Annals of Hematology

Lipid nanoparticle-mediated siRNA delivery for safe targeting of human CML in vivo

N. Jyotsana, A. Sharma, A. Chaturvedi, et al.

Read More 阅读更多

Publication - Summary

May 17, 2019

Science Immunology

A lipid-encapsulated mRNA encoding a potently neutralizing human monoclonal antibody protects against chikungunya infection

N. Kose, J.M. Fox, G. Sapparapu, et al.

Read More 阅读更多

Publication - Summary

April 04, 2019

The Journal of Neuroscience

PTCD1 is required for mitochondrial oxidative-phosphorylation: possible genetic association with Alzheimer's disease

D. Fleck, L. Phu, E. Verschueren, T. Hinkle, M. Reichelt, T. Bhangale, B. Haley, Y. Wang, R. Graham, D.S. Kirkpatrick, M...

Read More 阅读更多

Publication - Summary

February 07, 2019

Nano Research

Chemotherapy drugs derived nanoparticles encapsulating mRNA encoding tumor suppressor proteins to treat triple-negative breast can...

C. Zhang, X. Zhang, W. Zhao, C. Zeng, W. Li, B. Li, X. Luo, J. Li, J. Jiang, B. Deng, D.W. McComb, Y. Dong

Read More 阅读更多

Application Note

January 16, 2019

mRNA Lipid Nanoparticles: Robust low-volume production for screening high-value nanoparticle materials

Read More 阅读更多 PDF

Publication - Summary

September 24, 2018

Nucleic Acid Therapeutics

MicroRNAs Enable mRNA Therapeutics to Selectively Program Cancer Cells to Self-Destruct

R. Jain, JP. Frederick, EY. Huang, KE. Burke, DM. Mauger, EA. Andrianova, SJ. Farlow, S. Siddiqui, J. Pimentel, K. Cheun...

Read More 阅读更多
Resource Center 资源中心

Stay Informed

Sign up today to automatically receive new Precision NanoSystems application notes, conference posters, relevant science publications, and webinar invites.

MENU
菜单
X
X